Health Canada approves Pfizer BioNTech BA.4/BA.5 Omicron vaccineThe authorization says the vaccine can be given three to six months after a second dose of the primary vaccine series, or the most recent booster shot. Updated interim guidance on using Imvamune vaccine for monkeypox outbreaksNACI includes recommendation to use one-fifth the usual dose intradermally (off-label) for the second pre-exposure vaccination dose, in times of limited vaccine supply. Study tries to see if child vaccines and asthma are linked A number of scientists have wondered if aluminum, a vaccine additive that has been used for decades, had a role in allergies and asthma in children. Vaccines reduce risk of long-COVID in breakthrough infections by 41% Non-vaccinated have much higher rates of persistent symptoms post infection Canadian study builds on link between long COVID and autoimmune diseases like lupus The research was based on blood samples from patients who were diagnosed with COVID-19 between August 2020 and September 2021. Can school-aged children accurately self-collect nasal swabs for SARS-CoV-2 tests? Study compares results of nasal swabs for SARS-CoV-2 testing self-collected by children and adolescents with those collected by healthcare workers Interval of 6 months or more needed between rituximab treatment and COVID-19 vax Antibody response rates jumped from 17.3% to 66.7% with longer intervals. How effective are COVID-19 vaccines in preventing hospitalization? Large U.S. study compares hospitalization rates in unvaccinated, vaccinated and vaccinated plus booster dose individuals QUIZ: The latest on the flu shot As we head into fall and winter, it’s time to start thinking about influenza. Psychological distress may be a risk factor for post-COVID-19 conditions Depression, anxiety, worry, perceived stress or loneliness preceding SARS-CoV-2 infection may increase risk of developing “long” COVID symptoms. First Previous 31 32 33 34 35 Next Last
